igf1 mRNA in liver is abolished in mice expressing Cre recombinase. (A) A representative RNase protection assay (18) using the pMI-4 riboprobe shows that the level of liver igf1 mRNA is abolished in 6-week-old mice positive for Cre (+) and homozygous for the loxP-flanked igf1 allele (L/L+) as well as hemizygous null, loxP-flanked igf1 mice (N/L+) (Top). This reduction correlates with the liver igf1 genotype (Bottom). (B) Quantification of liver igf1 mRNA in mice with various genotypes (L/L−, n = 12; L/L+, n = 15; N/L−, n = 10; N/L+, n = 9). (C) A representative RNase protection assay using the pMI-4 riboprobe showing that igf1 mRNA levels in fat, muscle, kidney, heart, and spleen are not affected by the absence of liver igf1 mRNA in homozygous mice for the loxP-flanked igf1 allele (L/L) in the presence or absence of Cre recombinase. (D) Quantification of fat (L/L−, n = 6; L/L+, n = 10), muscle (L/L−, n = 3; L/L+, n = 5), kidney (L/L−, n = 5; L/L+, n = 9), heart (L/L−, n = 8; L/L+, n = 13), and spleen (L/L−, n = 8; L/L+ n = 14) igf1 mRNA in homozygous mice for the loxP-flanked igf1 allele (L/L) in the presence or absence of Cre recombinase. The protected bands corresponding to igf1 mRNA were corrected to the 18S rRNA by PhosphorImmaging (relative arbitrary units). Statistical analysis of igf1 mRNA gene expression in different tissues was performed by using t test. Values shown are mean ± SD.